SOX13 and acute myeloid leukemia: Therefore, although the pathway from IL-34 to Sox13 and downstream adverse phenotypes has been observed in AML, the molecular mechanisms including how IL-34 regulates the expression of Sox13, the downstream events of Sox13 leading to enhanced proliferation, more LSCs and subcutaneous infiltration have not been elucidated and deserve further exploration.